- The opioid epidemic has become a worldwide crisis, with more than 130 people dying every day from an overdose in the U.S. alone
- The psychedelics industry has shown to be a significant player in combatting the opioid crisis and is currently $200 million worth of investments
- It’s not just the addict who’s affected. It’s their family and friends as well – and communities
- Universal Ibogaine Inc. has a plan to curb the number of opioid-related deaths through its plant-based treatment approach
North America has been ravaged by the opioid crisis with people unknowingly consuming highly potent and dangerous substances legally prescribed. This has led to a rise in overdoses — currently, the number one reason people are dying under 50. The volume of medical emergencies in Vancouver’s Eastside alone would be a significant cause for concern, but the problem extends across all of Canada and the U.S.
Between 2016 and June 2019, over a quarter of the 4,559 overdose deaths in B.C. occurred in Vancouver, the hardest-hit city in Canada. Opioid overdoses do not discriminate either — the epidemic has affected regular white-collar and blue-collar individuals, not just those on the fringes of society.
Opioid overdoses have become all too commonplace in North America and many, including the National Institute on Drug Abuse, have pointed to the pharmaceutical industry as being a big part of the problem. According to the Institute, “In the late 1990’s, pharmaceutical companies reassured the medical community that patients would not become addicted to prescription opioid pain relievers, [so] healthcare providers began to prescribe them at greater rates.”